AN2 Therapeutics GAAP EPS of -$0.17
- AN2 Therapeutics press release (ANTX): Q3 GAAP EPS of -$0.17.
- The Company had cash, cash equivalents and investments of $80.2 million as of September 30, 2026. The Company projects that existing cash, cash equivalents, and investments will sustain operations into 2029 under the current operating plan.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.